About
A scientific information platform, and nothing else
Terminus Peptides is a UK scientific information platform focused on clear explanations of peptide research, evidence quality and laboratory standards.
Mission
Peptide research is widely discussed and poorly summarised. Findings from cell culture are reported in the same register as findings from controlled trials, mechanisms are described as though they were outcomes, and regulatory status is asserted by people with no source for the assertion.
The intent here is narrow and, we hope, useful: describe what has actually been studied, at what evidence level, with what limitations, and point readers to the primary and regulatory sources so they can check any of it themselves. Where something is unknown, say so.
Terminus Peptides also supplies research materials for laboratory use. That side of the business is kept deliberately apart from this one: the catalogue makes no scientific claim about anything it lists, the research profiles promote nothing, and prices are published openly on every product page rather than hidden behind an enquiry. Orders are arranged by enquiry, and nothing is supplied for human use. This site does not advise anyone about their health and does not attempt to make any compound sound promising.
Editorial principles
These are the rules content is written and reviewed against. The full policy is published separately.
Claims are sourceable or they are removed
Every substantive scientific claim should be traceable to a source. Where a claim cannot be sourced it is deleted rather than hedged into something vaguer that survives review.
Citations are never invented
No paper, author, DOI or trial identifier is fabricated. A citation that has not been checked by an editor carries a visible unverified marker so it cannot borrow authority from the verified ones beside it.
Evidence is reported at the level it was obtained
In vitro, animal, early human and established clinical findings are described separately and never merged. Where a level is empty, the page says so rather than leaving a gap for a reader to fill.
Regulatory status is sourced, not inferred
A compound’s UK classification is stated only with a citation to an authoritative body and a date of checking. Status elsewhere in the world, supplier labelling and common usage are not evidence of UK status.
Nothing is published because it is ready to be interesting
Records enter the dataset requiring both scientific and regulatory review, and generate no page until both are complete. The build enforces this rather than trusting the process.
Editorial content is independent of what is supplied
Research profiles are written from the published literature, and nothing in them is shaped by what appears in the trade catalogue. No dosing, reconstitution, preparation or administration information is published anywhere on this site. There are no testimonials, no transformation imagery and no discount codes, and no metadata targets transactional searches for medicines.
Read the full editorial policy and corrections policy.
Current publication status
Published openly because a library that shows what it has not yet reviewed is more honest than one that shows only what it has.
- Compound records held
- 67
- Awaiting review
- 0
- Published profiles
- 67
The 67 published profiles have each been through scientific and regulatory review before appearing; a small number are clearly-labelled fictional worked examples, kept to demonstrate the structure of a profile. The 0 records awaiting review generate no public page. Alongside the profiles, 4 articles and the laboratory standards section have been published.
Organisation details
- Legal name
- Waypoint Labs Ltd
- Company number
- 17418752
- Registered address
- 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
Materials are stored in the conditions stated on each product page until dispatch.
Getting in touch
Scientific corrections, citation suggestions, regulatory concerns and accessibility problems are all welcome through the contact page. Reports that name the page and the specific statement can be acted on quickly. You can also email info@terminuspeptides.co.uk.